POLICY STATEMENT

ADMINISTRATION OF BOTULINUM TOxin NEUROMODULATORS

Background

Botulinum toxins are neuromodulators produced from the bacteria of the family Bacillaceae. There are at least seven different serotypes but only type A and type B have clinical applications. Clostridium botulinum, the agent that causes botulism in humans, produces powerful endotoxins which block the release of acetylcholine at the neuromuscular junction, thus inhibiting muscle contraction.\textsuperscript{1,2} After over 30 years of research and development, clinical applications include: cervical dystonias, cranial nerve VII disorders (including hemifacial spasm), benign essential blepharospasm, general spasticity, strabismus, migraine headaches, hyperhidrosis, vocal cord dysfunction, anal fissures, urinary incontinence, bruxism, vasospastic disorders of the hand, and other conditions. Botulinum toxins are now an established component of facial rejuvenation.

The first FDA approval of Botulinum Toxin Type A, produced as Botox\textsuperscript{®}, was in 1979 for treatment of strabismus. FDA approval followed in 2002 for Botox Cosmetic\textsuperscript{®} to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines)\textsuperscript{3} and in 2013, for treatment of periorbital rhytides (“crow’s feet”).

As FDA actions for botulinum toxins are expected to increase, plastic surgeons should check to make sure they are up to date on the latest approvals. Any non-approved use is considered off-label.

As of 2016, FDA approved Botulinum Toxin Type A is available from three manufacturers:

- Botox\textsuperscript{®} and Botox Cosmetic\textsuperscript{®} (OnabotulinumtoxinA, manufactured by Allergan, Irvine, CA)
- Dysport\textsuperscript{®} (abobotulinumtoxinA, manufactured by Ipsen Ltd., Berkshire UK)
- Xeomin\textsuperscript{®} (incobotulinumtoxinA manufactured by Merz Pharmaceuticals, Frankfurt, Germany)

FDA approved Botulinum Toxin Type B is available as Myobloc\textsuperscript{®} (rimabotulinumtoxinB, Solstice Neurosciences, San Francisco, CA).

Other forms of Botulinum Toxin Type A and Type B are available worldwide but are NOT FDA approved and therefore not available in the United States. For purposes of this document, further discussion will be limited only to the three FDA approved Botulinum Toxin Type A (BTA): Botox Cosmetic\textsuperscript{®}, Dysport\textsuperscript{®}, and Xeomin\textsuperscript{®}.

The biologic activities of the three BTA products are more similar than different but according to the FDA, they should not be considered interchangeable. For example, the number of units used for a clinical indication cannot be directly compared, as, 10 units of Botox Cosmetic or Xeomin applied to a particular facial region may require 20 to 30 units of Dysport to achieve similar clinical effects. Additionally, the onset and duration of clinically evident effects may also not be the same. BTA typically requires 7 to 10 days to see full effects and the results last 3 to 4 months. Patient may be re-evaluated 2 weeks after an injection to determine if more treatment is needed. A more detailed clinical comparison of BTA products and applications is available.\textsuperscript{4}

Clinical decisions about the use of a drug are the purview of the physician.
POLICY STATEMENT ADMINISTRATION OF BOTULINUM TOXIN NEUROMODULATORS

Complications
Potential transient adverse local effects include but are not limited to: rash, pain, edema, erythema, ecchymosis, headache or hyperesthesia at the injection site. These are not necessarily related to the drug. There has also been a single report of a localized anaphylaxis in the lower limb following injection for foot dystonia. Systemic complications may include flu-like symptoms or distant skin rashes. There has also been one report of a respiratory arrest following the use of botulinum toxin type A for muscle spasticity. Other rare but more frequently reported events are adverse or undesirable soft tissue effects that relate mostly to technique and result in temporary soft tissue malposition (such as blepharoptosis, brow ptosis, cheek ptosis, and lower eyelid ectropion or retraction, etc.) Care should be used in the periorcular region as temporary upper and lower eyelid dysfunction may occur. In the event of upper eyelid ptosis after BTA injection, alpha 2-adrenergic agonist eye drops may be used to treat the ptosis.

Patients may develop non-responsiveness to BTA injections. This may be related to antibody formation but the specific mechanisms are not yet known.

Patient Selection
Not all individuals are candidates for BTA injections. Among those who should not receive such injections are those who are sensitive to the ingredients; patients with neuromuscular diseases (such as myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis); and pregnant (also lactating/breast feeding) women. Injections should be applied with caution and discretion in those patients on anticoagulation/aspirin therapy; patients treated with aminoglycosides, penicillamine, quinine, or calcium channel blockers, as these drugs have been known to possibly potentiate clinical effects. Patients who have unreasonable expectations or psychological issues that would preclude a satisfactory outcome should be excluded from treatment. Patients should understand that the effect of botulinum treatment can last several months but will not achieve a permanent change nor will it produce the same effect as surgical facial rejuvenation, including facelift. Surgical options should be considered if a more extensive change and longer-term result is desired.

Provider Qualifications
Despite the popularity and safety of BTA, it must be remembered that injection of BTA is a medical procedure. Patients are advised to have treatments with a qualified physician who understands neuromuscular and facial anatomy, facial aging and aesthetics, as well as potential neurotoxicity of the product. Under certain circumstances determined by the physician and applicable local and state professional practice regulations, injections may be administered by a licensed professional nurse or physician assistant. The individual physician of record, however, is ultimately responsible for both understanding and abiding by the applicable local and state professional practice regulations in determining the supervisory involvement required in each situation.
Risk Management Considerations
The injection of BTA is a medical procedure and is subject to the same precautions of any medical procedure. Treatment should be administered in the physician’s office or other clinical setting with appropriate medical personnel and necessary equipment to safely observe patients and deal with possible complications. As with any medical procedure, a complete patient record should be maintained. Patients should be fully informed as to the temporary nature of botulinum injections, the risks, benefits, alternatives and reasoning for the proposed treatment as well as off-label uses. Each patient should sign an informed consent statement. Patient photographic documentation before starting treatment may be useful. The medical record should indicate the lot number, dosage, injection sites and any noted adverse reaction of any kind. Documentation of adverse events should include reporting of such incidents to the manufacturer when applicable. Patients should have continuing access to the provider and be medically supervised for several weeks following treatment, should an adverse event occur. Disposal of medical waste should be handled in accord with Occupational Safety and Health Administration (OSHA) regulations.

Although extremely unlikely, epinephrine or other precautionary methods should be available to treat anaphylactic reactions. Signs and symptoms of overdose may not be immediately apparent, but treatment should be initiated immediately when an overdose is realized.10

Most BTA injections are done in a physician’s office but may also be done in a medical spa setting without a physician on site. State and local laws need to be followed in such cases. BTA injections in non-clinical settings (private homes, work events, group or social gatherings) may be inappropriate for several reasons, which include:

- inadequate patient selection by the provider
- inadequate individualized informed consent
- possible peer pressure for an individual to consent to treatment
- providers who are not trained in the administration of botulinum or qualified to assess or treat complications

The decision to have a medical procedure should be made without the influence of alcohol or peer pressure. If BTA is administered outside of a clinical setting, care should be taken to provide an appropriate environment for each patient and assure the same level of patient selection and informed consent as in a clinical environment.
POLICY STATEMENT

ADMINISTRATION OF BOTULINUM TOXIN NEUROMODULATORS

Ethical Considerations
The Code of Ethics of the American Society of Plastic Surgeons states that a member may be subject to disciplinary action, including expulsion, if the member participates in a charity raffle, fund raising event, contest or other promotion in which the prize is any procedure.\textsuperscript{11} For purposes of the Code of Ethics, BTA is NOT considered a medical procedure. However, the most current version of the Code should be reviewed prior to any such offering.\textsuperscript{12}

Conclusion
BTA injections can be a safe and effective temporary treatment of fine facial lines and wrinkles, can produce a temporary improvement of facial and periorbital shape, and can serve as a useful adjunct in a variety of plastic surgical procedures.\textsuperscript{13-14} Patients are advised to have treatments with a physician, or a provider designated by the physician, who is trained to give the injections and assess post-treatment effects. Board-certified plastic surgeons are ideally qualified to administer these injections because of their training.

\textit{Originally Approved by the American Society of Plastic Surgeons, Executive Committee, June 11, 2002. Updated and reaffirmed: June 2016}
POLICY STATEMENT

ADMINISTRATION OF BOTULINUM TOXIN NEUROMODULATORS

References


